These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
466 related articles for article (PubMed ID: 34510420)
21. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis. Jenkins J; Williams D; Deng Y; Collins DA; Kitchen VS Eur J Clin Pharmacol; 2010 Jan; 66(1):67-76. PubMed ID: 19756558 [TBL] [Abstract][Full Text] [Related]
22. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Ryu JY; Song IS; Sunwoo YE; Shon JH; Liu KH; Cha IJ; Shin JG Clin Pharmacol Ther; 2007 Nov; 82(5):531-40. PubMed ID: 17392720 [TBL] [Abstract][Full Text] [Related]
23. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. Ogasawara K; LoRusso PM; Olszanski AJ; Rixe O; Xu C; Yin J; Palmisano M; Krishna G Cancer Chemother Pharmacol; 2020 Jul; 86(1):87-95. PubMed ID: 32537715 [TBL] [Abstract][Full Text] [Related]
24. A Comprehensive In Vivo and In Vitro Assessment of the Drug Interaction Potential of Red Ginseng. Seong SJ; Kang WY; Heo JK; Jo J; Choi WG; Liu KH; Lee S; Choi MK; Han YH; Lee HS; Ohk B; Lee HW; Song IS; Yoon YR Clin Ther; 2018 Aug; 40(8):1322-1337. PubMed ID: 30078466 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of the impact of Polygonum capitatum, a traditional Chinese herbal medicine, on rat hepatic cytochrome P450 enzymes by using a cocktail of probe drugs. Zheng L; Lu Y; Cao X; Huang Y; Liu Y; Tang L; Liao SG; Wang AM; Li YJ; Lan YY; Wang YL J Ethnopharmacol; 2014 Dec; 158 Pt A():276-82. PubMed ID: 25446640 [TBL] [Abstract][Full Text] [Related]
26. Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach. Kim MG; Kim Y; Jeon JY; Kim DS Br J Clin Pharmacol; 2016 Dec; 82(6):1580-1590. PubMed ID: 27495955 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088 [TBL] [Abstract][Full Text] [Related]
31. Effect of commercial Rhodiola rosea on CYP enzyme activity in humans. Thu OK; Spigset O; Nilsen OG; Hellum B Eur J Clin Pharmacol; 2016 Mar; 72(3):295-300. PubMed ID: 26613955 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method. Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433 [TBL] [Abstract][Full Text] [Related]
33. RNA interference therapy in acute hepatic porphyrias. Yasuda M; Keel S; Balwani M Blood; 2023 Nov; 142(19):1589-1599. PubMed ID: 37027823 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic-pharmacodynamic model of urinary δ-aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria. Lee J; Melch M; Robbie GJ CPT Pharmacometrics Syst Pharmacol; 2023 Jun; 12(6):842-852. PubMed ID: 36883675 [TBL] [Abstract][Full Text] [Related]
35. A randomized, placebo-controlled study of givosiran in patients with acute hepatic porphyrias (ENVISION): Final (36-month) analysis of the Taiwan Cohort. Lee MJ; Kuo HC; Chou LN; Sweetser MT; Wang JD J Formos Med Assoc; 2024 Jun; 123(6):679-686. PubMed ID: 38044204 [TBL] [Abstract][Full Text] [Related]
36. Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit? Petrides PE; Klein M; Schuhmann E; Torkler H; Molitor B; Loehr C; Obermeier Z; Beykirch MK Ann Hematol; 2021 Jul; 100(7):1685-1693. PubMed ID: 34050373 [TBL] [Abstract][Full Text] [Related]
37. Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran. Ventura P; Sardh E; Longo N; Balwani M; Plutzky J; Gouya L; Phillips J; Rhyee S; Fanelli MJ; Sweetser MT; Petrides PE Expert Rev Gastroenterol Hepatol; 2022 Sep; 16(9):879-894. PubMed ID: 35929959 [TBL] [Abstract][Full Text] [Related]
38. Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations. Machavaram KK; Endo-Tsukude C; Terao K; Gill KL; Hatley OJ; Gardner I; Parrott N; Ducray PS AAPS J; 2019 Mar; 21(3):42. PubMed ID: 30887238 [TBL] [Abstract][Full Text] [Related]
39. An improved cytochrome P450 phenotyping cocktail with a simplified and highly sensitive UHPLC-MS/MS assay in human plasma. Eagles SK; Wang X; Gross AS; McLachlan AJ J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Mar; 1140():122013. PubMed ID: 32050158 [TBL] [Abstract][Full Text] [Related]
40. Inhibitory effects of kale ingestion on metabolism by cytochrome P450 enzymes in rats. Yamasaki I; Yamada M; Uotsu N; Teramoto S; Takayanagi R; Yamada Y Biomed Res; 2012; 33(4):235-42. PubMed ID: 22975634 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]